Light Therapy for Alzheimer's Disease

Recruiting at 1 trial location

Overseen By Mariana Figueiro, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Icahn School of Medicine at Mount Sinai

Must not be taking: Sleep medication, Melatonin

Disqualifiers: Brain vascular disease, Parkinson's, others

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Who Is on the Research Team?

Mariana Figueiro, PhD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Are You a Good Fit for This Trial?

This trial is for individuals with Alzheimer's Disease or Mild Cognitive Impairment. Participants will be involved in a study for 6 months, where they'll experience different lighting conditions to see how it affects their sleep, cognition, and mood.

Inclusion Criteria

I have Alzheimer's or similar dementia with a MoCA score below 25.

I have trouble sleeping, scoring 5 or more on a sleep quality test.

Exclusion Criteria

I am taking oral melatonin.

I use medication to help me sleep.

I have cataracts that block my vision.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either the active Tailored Lighting Intervention (TLI) or placebo for 6 months

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Active Lighting Intervention

Trial Overview The study tests the effects of Tailored Lighting Intervention (TLI) versus placebo lighting on patients' circadian systems. It aims to understand if specific light exposure can improve sleep and cognitive functions in Alzheimer's patients.

How Is the Trial Designed?

Group I: Active Lighting Intervention Active Control 1 Intervention

Combining spectrum and light level, the active TLI will allow the researchers to use a light source that will stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.

Group II: Control Lighting Intervention Placebo Group 1 Intervention

The control TLI will allow the researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+